Adaptive Biotechnologies Set to Announce Q2 2025 Earnings

Adaptive Biotechnologies Corporation is scheduled to release its earnings report for the second quarter of the 2025 fiscal year on August 5, 2025, after the market closes. Analysts predict the company will report an earnings loss of ($0.24) per share, alongside revenue of approximately $49.40 million for the quarter.

In its previous earnings report, released on May 1, 2025, Adaptive Biotechnologies surprised investors by reporting a loss of ($0.20) per share, which surpassed the consensus estimate of ($0.28) by $0.08. The company generated revenue of $52.44 million, significantly exceeding analysts’ expectations of $42.13 million. Year-over-year, this represents a notable increase of 25.2% in revenue.

The financial performance of Adaptive Biotechnologies reveals challenges, with a negative net margin of 74.84% and a negative return on equity of 62.79%. Over the current fiscal year, analysts forecast an earnings loss of $-1 per share, with similar expectations for the next fiscal year.

On the trading front, shares of Adaptive Biotechnologies opened at $10.33 on Friday. The stock has seen a 0.9% increase and currently holds a 50-day moving average price of $10.67 and a 200-day moving average price of $8.94. Over the past year, the stock has fluctuated between a low of $3.85 and a high of $12.43. The company’s market capitalization stands at $1.57 billion, with a price-to-earnings ratio of -10.76 and a beta of 1.92.

Recent Institutional Activity

Recent trading activity has seen significant changes in institutional holdings of Adaptive Biotechnologies. AQR Capital Management LLC boosted its stake by 45.8% during the first quarter, acquiring an additional 97,444 shares, bringing its total to 310,272 shares valued at $2,265,000.

Additionally, Caxton Associates LLP entered a new position in the company worth approximately $93,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. also increased its stake by 4.4% during the same period, now owning 68,830 shares valued at $511,000. Notably, institutional investors currently hold 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation focuses on developing an immune medicine platform aimed at diagnosing and treating various diseases. The company utilizes an immunosequencing platform that integrates proprietary chemistry, computational biology, and machine learning to produce clinical immunomics data, helping to decode the adaptive immune system.

Investors and analysts alike will be closely monitoring the upcoming earnings announcement as the company continues to navigate a challenging financial landscape while striving for growth in its innovative field.